Interleukin-2 for the treatment of human immunodeficiency virus infection

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Notwithstanding the significant impact of highly active antiretroviral therapy (HAART) on human immunodeficiency virus (HIV)-associated morbidity and mortality, HAART-induced immune restitution is not complete. The potential utility of interleukin (IL)-2 to augment immune function has been extensively evaluated. Intravenous or subcutaneous IL-2 has been conclusively shown to induce significant increases in CD4 cell counts in HIV-infected patients, in particular when given concomitantly with HAART. Large randomized clinical trials are underway to investigate whether these CD4 cell increments will result in tangible clinical benefits.

Original languageEnglish (US)
Pages (from-to)791-801
Number of pages11
JournalDrugs of Today
Volume42
Issue number12
DOIs
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Interleukin-2 for the treatment of human immunodeficiency virus infection'. Together they form a unique fingerprint.

  • Cite this